Clinical trial · Interventional
AML Electronic Decision Aid
A Pilot Feasibility and Preliminary Efficacy Study of an Electronic Decision Aid for Patients With Acute Myeloid Leukemia (AML)
NCT03442452CI-TRIAL-00041148completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to test the feasibility and preliminary efficacy of a novel electronic decision aid to improve AML patients' understanding of their illness, prognosis, and treatment options.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Electronic Decision Aid Tool | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Electronic Decision Aid
- description
- For this study, we will be testing a novel electronic decision aid to improve Acute Myeloid Leukemia patients' understanding of their illness, prognosis, and treatment options.
- interventionNames
- Other: Electronic Decision Aid Tool
Primary outcomes (1)
- measure
- Number of enrolled subjects who have completed the study
- timeFrame
- 1 day
- description
- Feasibility will be determined by enrolled subjects who complete the study (including watching all videos, and completing the surveys).
Secondary outcomes (1)
- measure
- Change in knowledge about AML after video viewing
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * At least age 18 * Capacity to give consent * Diagnosis of acute myeloid leukemia (AML) * Fluent in English * Receiving care at Duke, and fits into one of the following scenarios: * has not yet made a treatment decision (in the DCI clinics or on the inpatient wards), * have recently made a decision (in the last 6 weeks), and are admitted for chemotherapy on 9100 or in the oncology treatment center to receive outpatient therapy, * or, during remission, while receiving consolidation chemotherapy in the hospital Exclusion Criteria: * Patients too sick to participate per clinician discretion
References
Publications (1)
- DERIVEDHildenbrand JD, Davis DM, El-Jawahri A, Herring KW, Locke SC, Pollak KI, Samsa GP, Steinhauser KE, Troy JD, Ubel PA, Leblanc TW. A novel decision aid for acute myeloid leukemia: a feasibility and preliminary efficacy trial. Support Care Cancer. 2021 Jul;29(7):3563-3569. doi: 10.1007/s00520-020-05864-5. Epub 2020 Nov 6. PMID 33159220